Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California.
| Revenue (Most Recent Fiscal Year) | $22.27M |
| Net Income (Most Recent Fiscal Year) | $-40.47M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 12.83 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.72 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -522.48% |
| Net Margin (Trailing 12 Months) | -181.71% |
| Return on Equity (Trailing 12 Months) | -62.71% |
| Return on Assets (Trailing 12 Months) | -50.82% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.30 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.57 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.15 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.64 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 45.72M |
| Free Float | 40.92M |
| Market Capitalization | $285.73M |
| Average Volume (Last 20 Days) | 1.50M |
| Beta (Past 60 Months) | 0.59 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 21.68% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |